<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EB163B8B-DF59-4DB0-8A15-BD3FDF1B9E98"><gtr:id>EB163B8B-DF59-4DB0-8A15-BD3FDF1B9E98</gtr:id><gtr:name>Critical Pharmaceuticals Limited</gtr:name><gtr:address><gtr:line1>BIOCITY NOTTINGHAM , PENNYFOOT STREET</gtr:line1><gtr:city>NOTTINGHAM</gtr:city><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB163B8B-DF59-4DB0-8A15-BD3FDF1B9E98" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EB163B8B-DF59-4DB0-8A15-BD3FDF1B9E98</gtr:id><gtr:name>Critical Pharmaceuticals Limited</gtr:name><gtr:address><gtr:line1>BIOCITY NOTTINGHAM , PENNYFOOT STREET</gtr:line1><gtr:city>NOTTINGHAM</gtr:city><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>185629.0</gtr:offerGrant><gtr:projectCost>371258.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E759D7E3-677E-4743-A32B-B6E81EEFF4D9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>E759D7E3-677E-4743-A32B-B6E81EEFF4D9</gtr:id><gtr:name>Polytherics Limited</gtr:name><gtr:address><gtr:line1>BABRAHAM RESEARCH CAMPUS , BABRAHAM</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>155793.0</gtr:offerGrant><gtr:projectCost>311586.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6C6184CA-1CF5-49A1-A76B-235BE5FFE7AB"><gtr:id>6C6184CA-1CF5-49A1-A76B-235BE5FFE7AB</gtr:id><gtr:firstName>Tim</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101001"><gtr:id>5616F81D-B059-4592-9058-2E59A905350F</gtr:id><gtr:title>A novel injectable sustained release delivery system for the treatment of Hepatitis C</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101001</gtr:grantReference><gtr:abstractText>To address unmet clinical needs, protein-based medicines must be manufactured so as to overcome many limitations including their propensity to degrade and to clear rapidly from blood circulation. Our consortium has developed two proprietary technologies that are based on clinically proven strategies and address the inherent limitations of protein-based medicines. Critical Pharmaceuticals (CP) have developed novel biodegradable microparticles able to encapsulate proteins for prolonged continuous release. PolyTherics (PT) have developed technologies for site-specific PEGylation of proteins that result in the extension of their half-life while in circulation and an increase in their pharmaceutical stability. We propose to combine these technologies to produce high value products with enhanced performance where the combined technology is superior to the technologies used separately.</gtr:abstractText><gtr:fund><gtr:end>2014-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>341422</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101001</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>